Hosted on MSN
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%
Retail buzz around Summit Therapeutics picked up Sunday after the biotech reported what it called a first-of-its-kind result in a major lung cancer study, showing that its experimental antibody ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results